Global Biopharmaceutical M&A Is Accelerating in 2026

Global biopharmaceutical dealmaking has accelerated sharply in 2026 as pharmaceutical companies respond to a convergence of strategic pressures, including approaching patent expirations, rising demand for advanced therapeutics, intensified competition for innovation assets, and the rapid adoption of AI across drug development.

According to Bloomberg (2026), global biopharmaceutical M&A value has more than doubled year-over-year to approximately $66 billion, as large drugmakers increase acquisitions to strengthen future revenue pipelines and offset upcoming exclusivity losses on major therapies. 

Recent transactions suggest the industry is entering a more acquisition-driven phase of growth strategy, with companies increasingly using M&A to secure late-stage assets, access emerging technologies, and improve long-term pipeline visibility amid mounting pressure on internal R&D productivity. This article explores the main drivers behind the recent increase in biopharmaceutical M&A activity, including patent cliff pressures, demographic healthcare demand, AI-enabled drug development, and evolving strategic priorities across the pharmaceutical industry. 

1. Market Overview 

Biopharma M&A rebounded sharply in 2025 and remained active into early 2026 as pharmaceutical companies accelerated efforts to secure external innovation and offset future patent expirations. According to IQVIA, aggregate biopharma M&A value reached approximately $133 billion in 2025, more than doubling year-over-year, while J.P. Morgan estimates deal activity totalled roughly $40.9 billion across 32 transactions in Q1 2026. 

Biopharma M&A total deal value, by year – Source: IQVIA 

Biopharma M&A total deal value, in Q1 2026 – Source: JPMorgan 

Recent dealmaking reflects a continued shift toward targeted, innovation-driven acquisitions rather than large-scale consolidation. While mega-mergers remained limited, several transactions exceeded $10 billion in 2025, including Johnson & Johnson’s acquisition of Intra-Cellular Therapies, Novartis’s acquisition of Avidity Biosciences, and Pfizer’s acquisition of obesity-focused biotech Metsera. Competition has been particularly concentrated around oncology, obesity, immunology, and cardiometabolic disease, with acquirers prioritizing differentiated and commercially scalable assets. 

The market has also become increasingly selective and focused on de-risked opportunities. IQVIA estimates commercial-stage and Phase III assets accounted for more than three-quarters of total biopharma M&A value in 2025, while J.P. Morgan noted continued investor preference in Q1 2026 for programs with clearer clinical and commercial pathways. Licensing activity has also accelerated alongside acquisitions, with biopharma licensing partnerships reaching approximately $82.7 billion in announced value during Q1 2026 according to J.P. Morgan. 

2. Catalysts for the Surge in Biopharma Dealmaking 

Biopharma M&A activity accelerated significantly in 2025 as multiple structural, financial, and regulatory forces converged across the industry. Large pharmaceutical companies faced growing pressure to replenish revenues ahead of a major patent cliff, while simultaneously operating with substantial cash reserves and increased acquisition capacity. At the same time, improving regulatory visibility and a more predictable U.S. policy environment reduced execution risk for large-scale transactions. 

On the biotech side, constrained venture funding and a prolonged IPO slowdown continued to limit access to capital and exit opportunities, particularly for early- and mid-stage companies. This imbalance between strong pharmaceutical demand for innovation and weaker biotech financing conditions created a favorable environment for strategic acquisitions, partnerships, and licensing activity. Together, these factors contributed to a sharp resurgence in biopharma dealmaking during 2025. 

2.1. Mounting patent-expiry pressures 

According to CNBC (2026), the loss of exclusivity (LOE) is creating major pressure on the biopharma industry, driving a surge in biotech mergers and acquisitions (M&A). As blockbuster drugs approach patent expiration, known as the “patent cliff”, pharmaceutical companies risk losing significant revenue to generic and biosimilar competition. By 2032, LOE is expected to impact at least $173.9 billion in annual sales, with some estimates reaching $200–350 billion when smaller brands are included. 

To offset these looming revenue losses, large pharmaceutical companies are aggressively seeking new growth opportunities by acquiring biotech firms with promising drug pipelines, particularly in high-demand therapeutic areas such as obesity and weight loss. This urgency has intensified competition for high-value biotech assets, exemplified by bidding wars like the one between Pfizer and Novo Nordisk over Metsera. 

2.2 Industry Dry Powder and Improving Regulatory Visibility 

Another major catalyst behind the resurgence of biopharma M&A activity in 2025 was the combination of substantial industry “dry powder” and improving policy visibility across the pharmaceutical sector.  

According to IQVIA (2026), large pharmaceutical companies entered the year with strong balance sheets and significant acquisition capacity, big pharma’s deal capacity has steadily grown in recent years and is estimated at $1.3Tn today. Substantial cash reserves have increased acquisition capacity, particularly for mid-sized bolt-on transactions below $10 billion. 

Another factor supporting the acceleration of biopharma M&A activity in 2025 was the improvement in regulatory and policy visibility across the U.S. healthcare market. Earlier in the year, uncertainty surrounding potential pharmaceutical tariffs, most-favored-nation (MFN) drug pricing policies, and broader healthcare reforms contributed to a more cautious dealmaking environment, as companies assessed the potential impact on profitability and commercial strategy. 

By the second half of 2025, however, many of these concerns had become more manageable for large pharmaceutical companies. Through commitments to expand U.S. manufacturing and R&D investments, as well as agreements aligned with government priorities around Medicaid pricing and direct-to-patient affordability, companies were able to reduce exposure to tariffs and broader pricing mandates.  

At the same time, dealmakers benefited from a less interventionist antitrust environment in the U.S. Although the pharmaceutical sector continues to receive scrutiny from merger control and foreign direct investment authorities, particularly around acquisitions of innovative biotech firms, the Federal Trade Commission adopted a comparatively less activist stance toward large pharmaceutical transactions in 2025. Notably, all U.S. biopharma deals exceeding $9 billion in 2025 received clearance during their initial review period, reflecting a more predictable regulatory approval environment. 

2.3 Constrained Funding Environment and Limited Exit Pathways   

According to Reuters (2026), a tightening biotech funding environment became another catalyst for accelerated biopharma M&A activity in 2025. Biotech venture funding across the U.S. and Europe fell to $24 billion across 410 rounds, down 14% year-over-year and marking the second-lowest annual VC funding level in the past six years. At the same time, the IPO window remained largely shut: only 11 biotech companies listed on U.S. exchanges in 2025, a 55% decline from 2024 and far below the 79 and 104 IPOs recorded in 2020 and 2021, respectively. 

The combination of constrained private funding and limited public market exits increased pressure on biotech firms to seek alternative liquidity and commercialization pathways, making strategic acquisitions more attractive. For large pharmaceutical companies with strong balance sheets, this created opportunities to acquire innovative assets from capital-constrained biotech firms at relatively attractive valuations. 

Biopharma venture investment, by quarters, from 2021 – Q1 2026 – Source: JPMorgan 

3. Emerging Trends in Biopharma Dealmaking in 2026 

Biopharma deal activity is expected to remain resilient in 2026, with companies balancing acquisitions of innovative early-stage assets against later-stage therapies capable of generating near-term revenue. KPMG’s 2025 survey found that 62% of firms intend to target early-stage innovative assets, while 58% are prioritizing late-stage assets, reflecting a dual strategy focused on both long-term pipeline development and immediate commercial returns. 

Industry momentum from 2025 is expected to continue, with total biopharma M&A projected to reach approximately $140–160 billion in 2026, driven by mounting patent-expiry pressures, abundant acquisition capital, and ongoing financing constraints across the biotech sector. 

A key driver remains the industry’s looming patent cliff. Major blockbuster therapies including Keytruda, Eliquis, Opdivo, and Cosentyx are among those approaching patent expiry by the end of the decade. As a result, pharmaceutical companies are expected to accelerate portfolio renewal strategies and compete more aggressively for differentiated growth assets. 

At the same time, large pharmaceutical companies continue to possess substantial financial flexibility, with estimated deal capacity remaining around $1.3 trillion entering 2026. Rather than prioritizing mega-mergers, companies are increasingly focusing on mid-sized acquisitions, licensing agreements, and earlier-stage innovation opportunities that strengthen long-term strategic positioning and platform capabilities. 

On the supply side, emerging biotech companies now account for approximately 70% of all clinical-stage assets globally, with many remaining unpartnered. However, venture funding remains below historical levels and the biotech IPO market has only partially recovered, maintaining financing pressure across the sector. This environment is expected to continue driving biotech firms toward partnerships, licensing deals, and M&A exits as important pathways to capital and commercialization. 

Policy and regulatory conditions have also become more manageable compared to early 2025. Concerns surrounding U.S. tariffs and most-favored-nation drug pricing reforms have moderated, while a less interventionist antitrust environment has improved deal visibility. However, uncertainty remains around Medicare pricing initiatives, FDA capacity constraints, and upcoming European pharmaceutical reforms affecting intellectual property and market access frameworks. 

Another emerging trend is the growing importance of China as a global innovation source. Multinational pharmaceutical companies are increasingly pursuing licensing agreements and partnership structures involving Chinese biotech assets as competition for differentiated innovation intensifies globally. 

Overall, biopharma dealmaking in 2026 is expected to remain driven by strategic portfolio renewal, demand for innovative assets, and continued funding pressures across biotech, with mid-sized acquisitions and licensing transactions likely to dominate activity. 

References: 

Bloomberg. (2026, April 27). Sun Pharma secures bridge loan for $12 billion Organon purchase. Bloomberg News. https://www.bloomberg.com/news/articles/2026-04-27/sun-pharma-secures-bridge-loan-for-12-billion-organon-purchase  

CNBC. (2026). Big pharma race to snap up biotech assets as $170 billion patent cliff looms.  https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html 

Ernst & Young. (2024). Navigating pharma loss of exclusivity. https://www.ey.com/en_us/insights/life-sciences/navigating-pharma-loss-of-exclusivity 

IQVIA. (2026, January). Biopharma M&A outlook for 2026. https://www.iqvia.com/locations/emea/blogs/2026/01/biopharma-m-and-a-outlook-for-2026 

J.P. Morgan. (2026). Biopharma and medtech deal reports. https://www.jpmorgan.com/insights/markets-and-economy/outlook/biopharma-medtech-deal-reports 

Herbert Smith Freehills Kramer. (2026). Global M&A outlook 2026: Sector perspectives – Pharmaceuticals. https://www.hsfkramer.com/insights/reports/2026/global-ma-report-2026/sector-perspectives/pharmaceuticals 

McKinsey & Company. (2026). 2026 M&A trends: Navigating a rapidly rebounding market. https://www.mckinsey.com/~/media/mckinsey/business%20functions/m%20and%20a/our%20insights/top%20m%20and%20a%20trends%202026/2026-m-and-a-trends-navigating-a-rapidly-rebounding-market.pdf 

Reuters. (2026). Big pharma M&A set for mega year as patent expiries drive deal urgency. Reuters. https://www.reuters.com/legal/transactional/big-pharma-ma-set-mega-year-patent-expiries-drive-deal-urgency-2026-05-01/